Health
Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants – PharmiWeb.com
The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase…
- The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase 1 participants to evaluate the safety and tolerability of a booster vaccine
- Discussions with regulatory authorities are ongoing regarding an additional registration-enabling study using an mRNA vaccine with a variant sequence; this would provide a flexible solution for rapidly adapting the vaccine for use against the B.1.351 lineage or…
Continue Reading
-
General21 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
Noosa News24 hours agoSanta drops in for carols
-
General14 hours agoAshes engulfed by fresh DRS controversy as TV umpire gives Jamie Smith out despite RTS ‘murmur’
-
Noosa News19 hours agoMeticulously crafted home in heart of Noosa Heads